c Flashcards

1
Q

what is melanoma? how dangerous is it?

A
  • Malignant tumour of melanocytes

- Most dangerous/fatal

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

what is the incidence of melanoma + demographic?

A

Rising incidence: high in white, low in darker people

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

which areas can melanoma affect

A

skin, Mucosal surfaces (oral, conjunctival, vaginal) + uveal tract of eye

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

what are genetic risk factors for melanoma

A

family history (CDKN2A mutations can cause MAPK pathway activation), MC1R variants, light skin, red hair, DNA repair defects (xeroderma pigmentosum)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

what are environmental risk factors for melanoma

A

intense sun exposure, chronic sun exposure, equatorial latitudes, sunbeds, immunosuppression

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

what are phenotypic risk factors for melanoma

A

> 100 melanocytic nevi, atypical melanocytic nevi

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

what does the MAPK pathway regulate

A

cellular proliferation, growth and migration

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

what do CDKN2A mutations do

A
  • can cause MAPK pathway activation.
  • CDKN2A encodes tumour suppressor P16 that binds to CDK4/6 preventing formation of cyclin-D1-CDK4/6 complex which phosphorylates Rb inactiving it & leading to E2F release (promotes cell cycle progression)
  • mutation promotes cell cycle progression
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

what is the usual immune response to melanoma? what molecule interferes with this process & how?

A
  • CD8+ T cells recognise melanoma antigens + if activated properly kill them. CD4+ helper T cells & antibodies involved.
  • CTLA-4 inhibits T-cell activation by removing co-stimulatory signal.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

what immunotherapy drugs are made for melanoma

A

CTLA-4 blockade (ipilimumab) + checkpoint inhibitors (PDL1/PD1)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

where are KIT mutations found?

A

acral, mucosal melanomas + sun exposed skin (copy number amplifications or activating mutations of KIT)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

what genes could be activated in melanoma

A

-Activation mutations of NRAS gene & BRAF gene (high in those with intermittent UBV exp. But low in those with cumulative UBV)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

what are the subtypes of melanoma

A

Superficial spreading, nodular, lentigo maligna, acral lentiginous, unclassifiable

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

what are the characteristics of superficial spreading subtype of melanoma?

A
  • majority.
  • Common in white.
  • Trunk on men, legs of women.
  • De novo or pre-existing nevus.
  • Most show regression (grey. Hypo-or depigmentation) shows interaction of host immune system with tumour.
  • First grow horizontally, then vertically (forms bump)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

what are signs of melanoma regression?

A

grey. Hypo-or depigmentation shows interaction of host immune system with tumour

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

what are characteristics of nodular melanoma

A

=2nd common in white.

  • Trunk, head & neck.
  • M>F.
  • blue-black, sometimes pink-red nodule (can be ulcerated, bleeding).
  • Rapid.
  • No horizontal growth, only vertical.
17
Q

what are characteristics of lentigno maligna melanoma

A

-minority.
>60yrs – chronically sun-damaged.
-Face.
-Slow growing, asymmetric brown-black macule, colour variation & irregular border.
-Lentigo maligna (in situ) can lead to invasive lentigo maligna melanoma (5%) (sun damage)

18
Q

characteristics of acral lentignous melanoma

A
  • uncommon.
  • 7th decade.
  • Palms & soles in/around nail apparatus.
  • Not racist (black peeps don’t get others, get this, seen more commonly in them)
19
Q

what is amelanotic melanoma

A

lacks pigment

20
Q

how can you detect melanoma early

A

change in color, shape, size of pigmented skin lesion

21
Q

characteristics for public to detect melanoma

A

ABCDE:

-asymmetry, border irregularity, colour variation, diameter>5mm (>pencil eraser), evolving

22
Q

what is garbe’s rule

A

don’t ignore worries of patient, low threshold for biopsy

23
Q

what are differentials for melanoma

A

Basal cell carcinoma, seborrheic keratosis (harmless age>), dermatofibroma (benign tumour)

24
Q

what are poor prognostic features of melanoma

A

increased Breslow thickness >1mm (depth melanoma – from granular layer to bottom of tumour), ulceration, age, male, anatomical site (trunk, head, neck), LN

-Survival decreases as stage increases

25
what investigation for melanoma (to see features)?
Dermoscopy: improves diagnosis melanoma. findings shouldnt be considered in isolation. Hisotry/risk important. Excise lesion histology if needed (if in doubt, take it out)
26
global features of melanoma
asymmetry, multiple colours, reticular, globular, reticular-globular, homogenous, starbust
27
what are other potential features of melanoma
-Atypical network, streaks, atypical dots, globules, irregular blood vessels, regression structures, blue-white veil
28
managmenet for melanoma?
- Primary excision down to subcutaneous fat (2mm peripheral margin) - Wide excision (margin by Breslow depth, 5mm for in situ, 10mm for = 1mm) to prevent local recurrence/persistent disease
29
in melanoma what investigation to see potential lymph node spread?
Sentinel lymphoma node biopsy: primary spread node = sentinel node. Represent most likely nodes to contain metastasis. Offered for pT1b+. extracapsular spread on LMB needs LN dissection
30
what imaging for melanoma
stage III, IV & stage IIC without SLNB,. PET-CT, MRI brain.
31
what is a major prognostic factor for metastatic melanoma
LDH
32
what do you do if unresectable or metastatic melanoma
1. immunotherapy: CTLA-4 inhibition (unresectable/metastatic BRAF negative – ipilimumab). PDL1 inhibitors (nivolumab). 2. mutated oncogene targeted therapy: combo of BRAF inhibitor & MEK inhibitor
33
what used for staging melanoma
-Pathological, TNM (imaging + biopsy are used
34
demographics for keratinocyte dysplasia
Pale. UVB damage. M>W. 68 median age diagnosis.
35
what are types of keratinocyte dysplasia
1. Acitinic keratoses (dysplastic keratinocytes) 2. Bowen’s disease (squamous cell carcinoma in situ) 3. Sqaumous cell carcinoma (potential metatastasis/death) 4. Basal cell carcinoma (never metastases, locally invasive)
36
what are risk factors for keratinocyte carcinomas
UV (PUVA), fair, genetic syndromes (xeroderma pigmentosum, oculocutaneous albinism, muir torre syndrome, nevoid BCC syndrome), nevus sebaceous, porokeratosis, organ transplantation (immune drugs), chronic non-healing wounds, ionising radiation (airline pilots), chemical exposure (tar, hydrocarbons)
37
most common keratinocyte carcinoma
basal cell carcinoma